A company discussed on No Priors: AI, Machine Learning, Tech, & Startups.

Powering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg
Nov 12, 2026 · 39:16
Isomorphic Labs president Max Jaderberg tells Elad Gil that drug discovery must move from empirical trial and error onto computers, using predictive AI models that reach experimental accuracy. AlphaFold was the first proof deep learning could generalize in biology, prompting Isomorphic's 2021 founding. He blames the empirical process for drugs costing $1.5 billion over 15 years with flat approvals, and clinic failures after rat toxicity tests prove only ~30% predictive. Isomorphic generates proprietary data, builds its drug design engine in-house, and focuses on oncology and immunology while partnering with pharma. He argues precise molecule engineering unlocks multidrug cocktails modulating whole pathways and expects predictive disease biology to step-change within five years.

Beam: The Great American Open Model with ReflectionAI Co-Founder and CEO Misha Laskin
Oct 9, 2026 · 1:09:45
ReflectionAI co-founder and CEO Misha Laskin joins Sarah Guo to discuss Beam, the company's 500 billion parameter open-weight reasoning model, arguing open models will capture the majority of global token demand. He details Beam's training on 6,000 GB300s and RL on 10,000 GB300s for four weeks, making it 3-4X more reasoning-efficient than same-capability models, and says enterprises spending $100M-plus a year shift from renting to owning intelligence. He notes open tokens have flipped from 70-30 closed to 70-30 open, calls competition with China's open models healthy, and counters safety critiques citing Linus's Law and a closed model that hacked another company. He also describes AI compressing a multi-year PhD to a week and steady-state research teams of about 100 people.
Powered by PodHood